PIE13 (n = 10) Helgadóttir et al.15 (n = 30) Hunfeld et al.14 (n = 19)
Formulation Nexium capsules Actavis tablets MUPS tablets
Mealtimes 2 h post-dose 2 h post-dose 5 min post-dose
Sampling times (h post-dose)
0.25, 0.5, 0.75, 1, 1.5, 2, 4, 8, 10, and 24 Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, and 8 0.083, 1, 2, 3, 4, 5, 6, 7, and 8
Visit for sampling Day one Day one and day five Day five
Number of samples 85 821 158
Excluded samples 10 0 0
LLOQ (mg/L) 0.001 0.00503 0.0260
Male, n (%) Female, n (%) 0 10 (100%) 15 (50%) 15 (50%) 7 (37%) 12 (63%)
Age (years) 30 (21−43) 24 (18−46) 21 (18−27)
Weight (kg) 99 (56−126) 76 (62−107) 69 (54−89)
CYP2C19 Genotype
NA
NA
9 homEM 9 hetEM 1 PM
Abbreviations: LLOQ = lower limit of quantification, homEM = homozygous extensive metabolisers, hetEM = heterozygous extensive metabolisers, PM = poor metabolisers Abbreviations: LLOQ = lower limit of quantification, homEM = homozygous extensive metabolisers, hetEM = heterozygous extensive metabolisers, PM = poor metabolisers Abbreviations: LLOQ = lower limit of quantification, homEM = homozygous extensive metabolisers, hetEM = heterozygous extensive metabolisers, PM = poor metabolisers Abbreviations: LLOQ = lower limit of quantification, homEM = homozygous extensive metabolisers, hetEM = heterozygous extensive metabolisers, PM = poor metabolisers